Skip to main content
Politics

Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'

Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'

Feed excerpt — reported by NPR Politics

Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at NPR Politics →

Original Source

This article was syndicated from NPR Politics. All rights remain with the original publisher.